Physician profile
David Minzer
NPI 1174751135
$6,164.44
in general payments reported to CMS, 2019-2025
24 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $242 · 2021: $198 · 2022: $835 · 2023: $575 · 2024: $1,342 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,582.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,280.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $878.67 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $615.83 | 2019-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $393.75 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $371.60 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $359.71 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.56 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $278.09 | 2023-2025 | Arexvy, Nucala, Shingrix |
| Sanofi-Aventis U.S. LLC | $208.93 | 2019-2022 | |
| Exact Sciences Corporation | $206.18 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $197.32 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.40 | 2019-2024 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $150.00 | 2024 | Voquezna |
| Pharmacosmos Therapeutics INC. | $150.00 | 2024 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $146.43 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $125.00 | 2023 | Nuzyra |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Amarin Pharma, INC. | $57.88 | 2019-2021 | |
| Astellas Pharma US INC | $37.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.97 | 2019 | |
| Dexcom, INC. | $24.41 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $24.30 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.25 | 2023 | Linzess |
| Shield Therapeutics INC | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Minzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.